儿童和青少年癌症患者 CAR-T 细胞药物研发儿科战略论坛:ACCELERATE 与欧洲药品管理局合作、美国食品药品监督管理局参与
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE i
ALL SOURCES
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE i
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
这是一项早期 I 期注册临床试验,评估抗 CD19CAR-T 细胞治疗淋巴瘤、白血病的安全性、可行性及初步疗效。当前状态:招募中。计划入组 9 例。试验地点:中国 · 南通(共 1 个中心,其中中国 1 个)。登记号:NCT06756321。
Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults.
SOHO State of the Art Updates and Next Questions | Latest Advances in the Management of Primary Mediastinal B-Cell Lymphoma.
Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.
Infectious Complications Following CD30 Chimeric Antigen Receptor T-Cell Therapy in Adults.
共 6 条
MEMBER ACCOUNT
登录成功会直接打开下一页。